Bacterial proteases in IBD and IBS
暂无分享,去创建一个
Dirk Haller | Kerstin Mueller | D. Haller | M. Schemann | Natalie Steck | Michael Schemann | Natalie Steck | K. Mueller
[1] M. Denis,et al. TACE inhibition amplifies TNF-alpha-mediated colonic epithelial barrier disruption. , 2009, International journal of molecular medicine.
[2] J. Sallenave,et al. Modifying the Protease , Antiprotease Pattern by Elafin Overexpression Protects Mice From Colitis JEAN – , 2011 .
[3] M. Steinhoff,et al. Protease-activated receptor-2 activation: a major role in the pathogenesis of Porphyromonas gingivalis infection. , 2006, The American journal of pathology.
[4] B. de Strooper,et al. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[5] Michael A McGuckin,et al. Intestinal barrier dysfunction in inflammatory bowel diseases. , 2009, Inflammatory bowel diseases.
[6] M. Stacey,et al. Interaction of Mite Allergens Der P3 and Der P9 with Protease-Activated Receptor-2 Expressed by Lung Epithelial Cells1 , 2001, The Journal of Immunology.
[7] M. Steinhoff,et al. Role for protease activity in visceral pain in irritable bowel syndrome. , 2007, The Journal of clinical investigation.
[8] A. Nusrat,et al. Immunopathology and Infectious Diseases The Bacterial Virulence Factor Lymphostatin Compromises Intestinal Epithelial Barrier Function by Modulating Rho GTPases , 2010 .
[9] N. Vergnolle,et al. CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.
[10] A. Ford,et al. IBS in 2010: Advances in pathophysiology, diagnosis and treatment , 2011, Nature Reviews Gastroenterology &Hepatology.
[11] A. Franco,et al. Bacteroides fragilis toxin stimulates intestinal epithelial cell shedding and γ-secretase-dependent E-cadherin cleavage , 2007, Journal of Cell Science.
[12] Jung Ok Shim,et al. Gut Microbiota in Inflammatory Bowel Disease , 2013, Pediatric gastroenterology, hepatology & nutrition.
[13] P. Adamski,et al. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. , 2009, World journal of gastroenterology.
[14] G. Macfarlane,et al. Contribution of the microflora to proteolysis in the human large intestine. , 1988, The Journal of applied bacteriology.
[15] W. W. Lathem,et al. The StcE Protease Contributes to Intimate Adherence of Enterohemorrhagic Escherichia coli O157:H7 to Host Cells , 2005, Infection and Immunity.
[16] Young‐Mi Lee,et al. Expression of Protease-Activated Receptor 2 in Ulcerative Colitis , 2003, Inflammatory bowel diseases.
[17] P. Brigidi,et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.
[18] Takashi Shimizu,et al. Serratia marcescens Serralysin Induces Inflammatory Responses through Protease-Activated Receptor 2 , 2006, Infection and Immunity.
[19] J. Ballard,et al. Clostridium difficile Toxins: Mechanism of Action and Role in Disease , 2005, Clinical Microbiology Reviews.
[20] A. Azghani. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. , 1996, American journal of respiratory cell and molecular biology.
[21] G. Rogler,et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo , 2006, Clinical and experimental immunology.
[22] Anne Salonen,et al. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. , 2010, Microbiology.
[23] B. Fingleton,et al. Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Philip Sutton,et al. Mucin dynamics and enteric pathogens , 2011, Nature Reviews Microbiology.
[25] B. Kuster,et al. Enterococcus faecalis metalloprotease compromises epithelial barrier and contributes to intestinal inflammation. , 2011, Gastroenterology.
[26] J. Potempa,et al. Cleavage and activation of proteinase‐activated receptor‐2 on human neutrophils by gingipain‐R from Porphyromonas gingivalis , 1998, FEBS letters.
[27] I. Autenrieth,et al. Gene-environment interactions in chronic inflammatory disease , 2011, Nature Immunology.
[28] A. Keshavarzian,et al. Regulation of Oxidant-Induced Intestinal Permeability by Metalloprotease-Dependent Epidermal Growth Factor Receptor Signaling , 2007, Journal of Pharmacology and Experimental Therapeutics.
[29] J. Platt,et al. Conditional signaling by Toll‐like receptor 4 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[30] B. Oneda,et al. The Metalloprotease Meprinβ Processes E-Cadherin and Weakens Intercellular Adhesion , 2008, PloS one.
[31] T. Kirkegaard,et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium , 2009, Clinical and experimental immunology.
[32] S. Bruno,et al. Increased thrombin generation in inflammatory bowel diseases. , 2008, Thrombosis research.
[33] P. Kenny. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer , 2007, Expert opinion on therapeutic targets.
[34] R. Spiller. Overlap between Irritable Bowel Syndrome and Inflammatory Bowel Disease , 2010, Digestive Diseases.
[35] David F. Tunmore,et al. The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. , 2000, The American journal of pathology.
[36] E. Nemoto,et al. Proteolysis of Human Monocyte CD14 by Cysteine Proteinases (Gingipains) from Porphyromonas gingivalis Leading to Lipopolysaccharide Hyporesponsiveness1 , 2000, The Journal of Immunology.
[37] David C. Lee,et al. An essential role for ectodomain shedding in mammalian development. , 1998, Science.
[38] A. Steele,et al. Anthrax lethal toxin induces endothelial barrier dysfunction. , 2005, The American journal of pathology.
[39] S. Michalek,et al. Characterization of Porphyromonas gingivalis-Induced Degradation of Epithelial Cell Junctional Complexes , 2000, Infection and Immunity.
[40] J. Potempa,et al. Activation of protease-activated receptors by gingipains from Porphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity. , 2001, Blood.
[41] G. Tannock. The search for disease-associated compositional shifts in bowel bacterial communities of humans. , 2008, Trends in microbiology.
[42] P. Cossart,et al. Candida albicans internalization by host cells is mediated by a clathrin‐dependent mechanism , 2009, Cellular microbiology.
[43] A. Tursi,et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. , 2004, Medical science monitor : international medical journal of experimental and clinical research.
[44] S. Filler,et al. Als3 Is a Candida albicans Invasin That Binds to Cadherins and Induces Endocytosis by Host Cells , 2007, PLoS biology.
[45] T. Kirkegaard,et al. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. , 2004, Clinical and experimental immunology.
[46] G. Schneider,et al. Helicobacter pylori HtrA is a new secreted virulence factor that cleaves E‐cadherin to disrupt intercellular adhesion , 2010, EMBO reports.
[47] F. F. di Mola,et al. Beneficial Effects of Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in Rat Experimental Colitis , 2001, Digestion.
[48] Y. Naito,et al. Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis , 2006, Scandinavian journal of gastroenterology.
[49] S. Rosewicz,et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease , 2000, Gut.
[50] J. Doré,et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients , 2008, Proceedings of the National Academy of Sciences.
[51] C. Rudack,et al. Immunomodulation of Nasal Epithelial Cells by Staphylococcus aureus-Derived Serine Proteases1 , 2009, The Journal of Immunology.
[52] F. Nagy,et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[53] M. Steinhoff,et al. Protease‐activated receptor‐4 (PAR4): a role as inhibitor of visceral pain and hypersensitivity , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[54] G. Gerken,et al. Trypsin-Sensitive Modulation of Intestinal Epithelial MD-2 as Mechanism of Lipopolysaccharide Tolerance1 , 2006, The Journal of Immunology.
[55] P. Cossart,et al. E-Cadherin Is the Receptor for Internalin, a Surface Protein Required for Entry of L. monocytogenes into Epithelial Cells , 1996, Cell.
[56] T. Wittmann,et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice , 2009, PAIN®.
[57] N. Bunnett,et al. Protease-activated receptors: protease signaling in the gastrointestinal tract. , 2004, Current opinion in pharmacology.
[58] M. Kreis,et al. Activity of protease-activated receptors in the human submucous plexus. , 2011, Gastroenterology.
[59] M. Sinnamon,et al. Essential role for mast cell tryptase in acute experimental colitis , 2010, Proceedings of the National Academy of Sciences.
[60] M. D'Andrea,et al. Arginine-Specific Protease fromPorphyromonas gingivalis Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion , 2001, Infection and Immunity.
[61] P. Bork,et al. A human gut microbial gene catalogue established by metagenomic sequencing , 2010, Nature.
[62] T. Kirkegaard,et al. Tumour necrosis factor‐α converting enzyme (TACE) activity in human colonic epithelial cells 1 , 2004 .
[63] K. Magnusson,et al. Distinct effects of Vibrio cholerae haemagglutinin/protease on the structure and localization of the tight junction‐associated proteins occludin and ZO‐1 , 2000, Cellular microbiology.
[64] J. Kennedy,et al. Faecal mucus degrading glycosidases in ulcerative colitis and Crohn's disease. , 1985, Gut.
[65] C. J. Taylor,et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. , 1999, Gastroenterology.
[66] Hannes Hahne,et al. T2025 Probiotic-Derived Lactocepin Degrades the Pro-Inflammatory Chemokine IP-10: Impact on Chronic Intestinal Inflammation , 2010 .
[67] M. Steinhoff,et al. Protease‐activated receptor‐4: a novel mechanism of inflammatory pain modulation , 2007, British journal of pharmacology.
[68] A. Azghani,et al. A bacterial protease perturbs the paracellular barrier function of transporting epithelial monolayers in culture , 1993, Infection and immunity.
[69] Liping Su,et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. , 2009, Gastroenterology.
[70] G. Berx,et al. The cell-cell adhesion molecule E-cadherin , 2008, Cellular and Molecular Life Sciences.
[71] Michael A McGuckin,et al. Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro Utilization of Mucin by Other Bacteria , 2010, The American Journal of Gastroenterology.
[72] J. D. de Paula,et al. Colonic proteinases: increased activity in patients with ulcerative colitis. , 1998, Medicina.
[73] C. Josenhans,et al. The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models , 2010, Nature Reviews Microbiology.
[74] M. Radomski,et al. Matrix metalloproteinase‐9 modulates intestinal injury in rats with transmural colitis , 2006, Journal of leukocyte biology.
[75] P. Garg,et al. Matrix metalloproteinases in inflammatory bowel disease: Boon or a bane? , 2007, Inflammatory bowel diseases.
[76] S. Vanner,et al. Activation of protease‐activated receptor‐4 inhibits the intrinsic excitability of colonic dorsal root ganglia neurons , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[77] C. Schultsz,et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. , 1999, Gastroenterology.
[78] F. Bistoni,et al. The contribution of PARs to inflammation and immunity to fungi , 2008, Mucosal Immunology.
[79] P. Bercik,et al. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. , 2010, Infectious disease clinics of North America.
[80] L. I. Bouwman,et al. Cleavage and activation of a Toll-like receptor by microbial proteases , 2011, Proceedings of the National Academy of Sciences.
[81] M. Chignard,et al. Increased Proteolytic Activity at Mucosal Surfaces in IBD Patients: A Possible Role for Elafin , 2011 .
[82] R. Langer,et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. , 2009, Gastroenterology.
[83] H. Birkedal‐Hansen,et al. Matrix metalloproteinases: a review. , 1993, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[84] K. O'Byrne,et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[85] A. Nusrat,et al. Role of the intestinal barrier in inflammatory bowel disease. , 2008, World journal of gastroenterology.
[86] M. Mareel,et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. , 2001, Journal of cell science.
[87] A. Zinsmeister,et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[88] Parsons,et al. The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease , 1999, Alimentary pharmacology & therapeutics.
[89] Y. Higashimoto,et al. A novel secreted protease from Pseudomonas aeruginosa activates NF‐κB through protease‐activated receptors , 2008, Cellular microbiology.
[90] F. Shanahan,et al. Degradation of the extracellular matrix components by bacterial‐derived metalloproteases: Implications for inflammatory bowel diseases , 2011, Inflammatory bowel diseases.
[91] G. Barbara,et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. , 2007, Gastroenterology.
[92] J. d'Alayer,et al. Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. , 2005, American journal of respiratory cell and molecular biology.
[93] R Balfour Sartor,et al. Microbial influences in inflammatory bowel diseases. , 2008, Gastroenterology.
[94] Y. Fujiyama,et al. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. , 1993, Internal medicine.
[95] Paul Forsythe,et al. Lactobacillus reuteri enhances excitability of colonic AH neurons by inhibiting calcium‐dependent potassium channel opening , 2009, Journal of cellular and molecular medicine.
[96] Ruth Ley,et al. Unravelling the effects of the environment and host genotype on the gut microbiome , 2011, Nature Reviews Microbiology.